Skip to main content
International Journal of Clinical and Experimental Pathology logoLink to International Journal of Clinical and Experimental Pathology
. 2017 Aug 1;10(8):9092–9103.

Lichen extracts regulate the expression of BMP7 via miR-194-5p targeting to decrease the risk atrial fibrillation

Kailin Zhao 1,*, Liyun Xiao 2,*, Meili Zhao 2, Changjian Ji 2
PMCID: PMC6965457  PMID: 31966782

Abstract

Background: Atrial fibrillation (AF), the most common cardiac supraventricular arrhythmia, affects more than 5 million people worldwide. Increasing evidence has demonstrated that genetic factors play an important role in the pathogenesis of AF, and multiple genes responsible for AF have been identified. A better understanding of the genetic mechanism underlying AF would be expected to lead to more accurate risk stratification of AF and optimal clinical treatment strategies. Methods: Immunofluorescence staining was performed to find the components which would have effects on the H9c2 cells development. The changes of BMP7 and miR-194-5p expressions were detected before and after Human Cardiac Myocytes (HCM) were treated with Lichen extraction. In order to confirm whether Lichen could increase the expression of BMP7 through inhibiting the expression of miR-194-5p, the mRNA levels of BMP7 and miR-194-5p were determined in HCM before and after the treatment of Lichen on the conditions that miR-194-5p was over-expressed or not. Results: After 48 hours’ treatment with 20 µg/mL Lichen extracts, the Collagen I expression level significantly decreased. The expressions of several genes in H9c2 cells could were changed after the treatment of Lichen extracts and some mRNA of them could also be targeted by miR-194-5p including BMP7. Lichen could depress the expression of miR-194-5p in HCM no matter miR-194-5p was overexpressed or not and correspondingly, the expression of BMP7 could be increased in both conditions. Conclusions: It is indicated that Lichen extracts could regulate the expression of atrial fibrillation-associated genes via miR-194-5a targeting.

Keywords: Atrial fibrillation, lichen, BMP7, miR-194-5p, traditional Chinese herbal preparation

Introduction

Atrial fibrillation (AF) is the most common cardiac supraventricular arrhythmia with the prevalence increasing markedly with age, which ranges from approximately 1% in general population to 10% in those aged over 75 years old [1]. The morbidity of AF is estimated to increase five-fold by 2050 along with the accelerating aging population [2]. The presence of atrial fibrillation can cause serious complications and can independently increase the risk of mortality and morbidity of patients [3]. Atrial fibrillation confers a five-fold increase in the risk of stroke and approximately doubles mortality, resulting in a major financial burden to patients and healthcare systems [4]. Generally, AF is known as a common complication in various cardiac and systemic disorders. While in some cases, AF can also exist in the absence of predisposing factors and is defined as lone AF [5].

While the underlying mechanisms of atrial fibrillation are complex and not well understood, multiple potential pathways and risk factors have been investigated. Since the first locus (10q22-q24) was identified in 1997, a number of atrial fibrillation-related genes have been identified and emerging evidenceswhich are strongly implicated with hereditary determinants for AF have been found as well [6]. From then on, researchers have identified and confirmed at least 25 genes which are related with AF. Mutations have also been identified in patient population with AF complicated with other disorders. Recent data have shown that almost all sodium channel genes and potassium channel genes are involved in the development of AF [7]. Makiyama. et al revealed that the SCN5A mutation P.M1875T which displays a gain-of-function modulation of cardiac Na+ channels is associated with familial AF, it also provided us a novel mechanism that predisposes to increased atrial excitability and familial AF [8,9]. KCNA5 encodesa member of the potassium channel producing ultra-rapid delayed rectifier potassium current, on which locus mutations can result in a loss-of-function effect on potassium current and eventually lead to AF [10-12]. However, as we all know that the mechanisms of AF are complex, and the maintenance of sinus rhythm after pharmacological or interventional treatments remains very challenging.

In this case, if we could find some chemical components which canalter expression levels of the AF-related genes resulting in the suppression of AF [13-16], it will be an important step forward to cure AF and relieve the pain that the patients suffer from. In this study, we tried to screen out some chemical components from traditionalChinese herbal preparation which have some effects on regulating the expression of some AF-related genes. Bmp7, Lox, Mmp3, Mmp8, Mmp9, Serpine I, Acta2, Ctgf, Grem1, Col1a2, and Col3a1 were choosed for their reported functions in AF. BMP7 encodes bone morphogenetic protein 7, which plays a key role in the transformation of mesenchymal cells into bone and cartilage. It has been reported that it could inhibit the fibrosis of heart and kidney [17].

Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) has the synergistic effect with TGF-β1 in myocardial fibrosis and Increased expression of LOX has been observed in left atria of patients with AF [18,19]. MMPs has been reported to correlate with human AF [20]. Patients with AF always have higher Serpine I levels which is implicated in the development of atrial fibrillation. Elevated levels of Serpine independently predict development of AF after cardiac surgery as well [21,22]. Acta2, also known as α-SMA, is a major constituent of the contractile apparatus and has a positive correlation with fibrosis [23]. CTGF, also called CCN2 or connective tissue growth factor, plays an important role in fibrotic diseases, whose over-expression could promote fibrosis in human [24-26]. Grem1 is the antagonist of bone morphogenetic proteins (BMPs) which could inhibit BMP-2, BMP-4, and BMP-7 in the TGF beta signaling pathway, so that it could accelerate organ fibrosis [27-29]. Collagen alpha-2 (I) chain (COL1A2) is one of the chains for type I collagen, the fibrillar collagen which has a positive correlation with human organ fibrosis [30,31].COL3A1 is a fibrillar collagen that is always related to type I collagen [32].

Some of the herbal preparations are usually used to treat systemic disorders or valvar heart disease, as we all know that valvar heart disease, hypertension, ischemic heart disease and hyperthyroidism are the most common causal risk factors of atrial fibrillation [33,34]. Furthermore, we found that aftertreating the H9c2 cells with Lichen extracts for 48 hours, the chosen AF-related genesin H9c2 cell lines were significantly changed compared with untreated cells and the cells treated with other extracts or chemical components. It was noted that the expression of BMP7 was obviously upregulated in both levels of mRNA and protein. It has been speculated that the mRNA of BMP7 is the target of miR-194-5p which is always upregulated in the patients with heart failure (HF) after acute myocardial infarction (AMI) [35,36]. While it has been displayed that AF is bidirectional associated with AMI, which means the risk of AF could be bigger when the risk of AMI is bigger [37-40]. According to this, we hypothesized that in patients with AF, BMP7 was inhibited by overexpressed miR-194-5p to lead to fibrosis, then promoted the progress of AF. In order to prove it, we treated human cardiac myocytes (HCM) with Lichen extracts and performed luciferase assay to reveal the mechanism underlying the inhibition of AF through regulating miR-194-5p or BMP7.

Materials and methods

Cell culture and reagents

H9c2 (2-1) rat heart myoblasts [15] were obtained from the American Type Culture Collection. Human cardiac myocytes (HCM) were obtained from Scien Cell Research Laboratories (Catalog Number: 6200, San Diego, CA, USA). Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% (v/v) fetal calf serum, glutamine (2 mM), non-essential amino acids [1% (v/v)] and gentamicin (100 mg/l) under an atmosphere of 5% CO2 in air saturated with water vapors at 37°C. The medium was replaced every 2 days. Cells were grown to confluence as monolayers and were split by treatment with trypsin. Stock solutions of (-)-isoproterenol, (-)-propranolol and dexamethasone were prepared in water and then diluted directly in DMEM. Untreated cells used as control were grown in the same DMEM to which only water was added.

Immunofluorescence staining

Cells were divided into the following treatment groups (n=10 wells): 1) Rabbit anticollagen I antibody (1:200 dilution; Catalog Number: Ab6308; Abcam); 2) Rabbit α-actinine antibody (1:400 dilution); 3) 10 mM PBS (control). The cells were cultured for 48 h, fixed in 4% paraformaldehyde, and blocked with goat serum. They were then incubated with the above-mentioned primary antibodies for 1 h and fixed at 4°C in a wet box overnight. Cells incubated with 10 mM PBS served as the control for the antibody staining. Next, the cells were treated with FITC-labeled goat anti-rabbit IgG (1:100 dilution, Catalog Number: 28176-05-FITC; Seebio), incubated at room temperature in a wet box for 1 hour, and stained in 0.5 μg/mL DAPI solution for 1 min. After washing the cells with PBS, five visual fields in each slide were randomly selected under a fluorescence microscope (400× magnification) and observed. The images were processed using the Image-Pro plus 6.0 (Media Cybernetics, USA) Image Processing Software to obtain the absorbance values at the same time of exposure. All the experiments were performed in the same condition for at least three individual repeats.

Q-PCR analysis

Total RNA from H9c2 cells was extracted by binding to a silica-based membrane using a microspin column technique according to the manufacturer’s protocol (Catalog. Number: 15596-026; Invitrogen TRIZOL® Reagent). Remaining traces of DNA were digested in a total volume of 100 µl with 10 units of DNaseI (FPLCpure, Pharmacia, Freiburg, Germany) in a buffer containing 10 mM Tris/HCl/10 mM MgCl2/50 mM KCl/10 mM dithiothreitol (pH 9.0) for 20 min at 37°C. With an additional clean-up procedure, DNaseI-treated RNA was recovered by adsorption on silica-based membranes as described in the total RNA extraction procedure.

cDNA synthesis was carried out in a 20 µL reverse transcription reaction containing 1 μg of total RNA, and various amounts of the corresponding internal standard RNA. RNA was reverse transcribed in a buffer containing 5 mM MgCl2, 50 mM KCl, 10 mM Tris/HCl (pH 8.3), 1 mM dNTPs, 2.5 µM random hexamers, and 20 units of RNase inhibitor and 100 units of RT. The reaction was performed at 42°C for 20 min. Thereafter, the mixture was incubated at 99°C for 5 min to inactivate the enzyme’s activity. Quantitative real-time PCR was performed on BioRad Connet Real-Time PCR platform using SYBR Green Master Mix Kit. In brief, each PCR reaction mixture containing 7.5 µL of 2× SYBR premix ex taq, 0.5 µL of sense and antisense primers (2.5 µM), 1 µl of cDNA and 5.5 µL of ddH2O, were run for 1 cycle of initial denaturation at 95°C for 30 s, and run for 40 cycles of denaturation at 95°C for 5 s and extension at 64°C for 34 s. The expression level of GAPDH was used as an internal control for normalization. All the primers were designed (Sequences of the primers are listed in Table 2). Relative gene expression levels were calculated using 2-ΔΔCT analysis. All the experiments were performed in the same condition for at least three individual repeats.

Table 2.

Primers used for Q-PCR

Gene names Sequence (5’-3’)
Col1a2 F GCCAAGAATGCATACAGCCG
R GACACCCCTTCTGCGTTGTA
Mmp8 F CGGGGTATTGGAGGAGATGC
R ATGAGCAGCCACGAGAAACA
Mmp9 F GATCCCCAGAGCGTTACTCG
R GTTGTGGAAACTCACACGCC
Serpine1 F CAACCCACTACGCCTTCACT
R TCTGTCTATCTGCTGCCCCT
Mmp3 F ATGGGCCTGGAATGGTCTTG
R TGTGGGAGGTCCATAGAGGG
Col3a1 F CAACCCACTACGCCTTCACT
R GCCACGTTCACCAGTTTCAC
LOX F GACCACAGGGTACTGCTACG
R CCACTCTCCTCTGTGTGCTG
Bmp7 F CGGAGGTTCATCTCCGTAGC
R GCTGTTTTCTGCCACACTGG
Grem1 F GACAGAATGAATCGCACGGC
R CGCTTCAGGTATTTGCGCTC
Ctgf F ACACAAGGGTCTCTTCTGCG
R ACTCCTCACAGCATTTCCCG
Acta2 F ACTCCTCACAGCATTTCCCG
R CTGTCAGCAATGCCTGGGTA
GAPDH F TCACCACCATGGAGAAGGC
R GCTAAGCAGTTGGTGGTGCA

Western blot analysis

H9c2 cells were homogenized in a lysis buffer containing 150 mM NaCl, 50 mM Tris·HCl, 10 mM EDTA, 0.1% Tween-20, 1% Triton, 0.1% β-mercaptoethanol, 0.1 Mm phenylmethylsulfonyl fluoride, 5 μg/mL leupeptin, and 5 μg/ml aprotinin (pH 7.4) and allowed to be incubated for 1 h on ice. Homogenates were then centrifuged at 4°C for 10 min at 10,000 g, and supernatants were collected. Protein concentrations were measured in the supernatants using a protein assay kit (Bio-Rad). Samples with equal amounts of proteins were loaded onto 10% polyacrylamide gel with 0.1% sodium dodecyl sulfate and separated by electrophoresis at 120 V for 1.5 h. Proteins were then transferred onto nitrocellulose membranes. Nonspecific binding sites were blocked for 1 h at room temperature in the Tris-buffered saline solution containing 5% dry milk. The membranes were then probed with primary antibodies (1:5,000 dilution, Abcam). To assure equal loading, band intensities were normalized to actin (1:5,000 dilution, Sigma). After being washed, membranes were incubated with secondary horseradish peroxidase-conjugated antibodies (1:10,000 dilution; Catalog Number: SC-2054; Santa Cruz) for 1 h. Proteins were visualized with enhanced chemiluminescence reagents, and blots were exposed to Hyperfilm. The results were analyzed with the Kodak ID image analysis software. All the experiments were performed in the same condition for at least three individual repeats.

Luciferase activity assay

A fragment of the wild-type (WT) BMP7 3’UTR containing the predicted miR-194-5p binding site was amplified by RT-PCR. The primers used were 5’-CGGAGGTTCATCTCCGTAGC-3’ (forward) and 5’-GCTGTTTTCTGCCACACTGG-3’ (reverse). Site-directed mutagenesis of the miR-194-5p target site was carried out using Stratagene Quik-Change site-directed mutagenesis kit (Stratagene, Heidelberg, Germany). The construct was sequenced and named BMP7-UTR-Mut. The pMIR-report luciferase vector was used for the construction of BMP7-UTR or BMP7-UTR-Mut plasmids (Ambion, USA). HCM cells were cultured in 24-well plates. In each well, 10 ng of phRL-TK renillaluciferase vector (Promega, USA) was co-transfected to normalize transfection efficiency. A concentration of 500 ng of BMP7-UTR or BMP7-UTR-Mut plasmids together with 10 nM miR-194-5p mimics or negative control was also co-transfected. Transfection was done using Lipofectamine 2000 and Opti-MEM I-reduced serum medium (Life Technologies, California, USA). Firefly luciferase activity was measured using the Dual luciferase assay kit (Promega). Normalized relative luciferase activity (RLA) was calculated as the following formula: RLA=[firefly luciferase]/[renilla luciferase] [41].

Statistical analysis

Data were expressed as means ± SE. Statistical significance (P<0.05) was determined by analysis of variance (ANOVA) followed by Newman-Keuls post hoc testing or Student’s t-test, where appropriate.

Results

Screening for candidate components

In order to find some candidate components, we selected a series of traditional Chinese herbal preparations (all the details are shown in Table 1) and added equal volume with the same concentration per well, i.e. 20 μg/ml extract or herbal preparation. After the treatment, immunofluorescence staining was performed to find the components which would have effects on the H9c2 cells development. Interestingly, we found that after 48 h of treatment with 20 μg/mL Lichen extracts, Collagen I expression level was significantly down regulated, comparing with the control (Figure 1A).

Table 1.

Dosing sequence and drug concentration per well

H9c2 Dosing sequence\drug concentration per well 20 μg/ml

1 2 3 4 5 6 7 8
A Emodin Lichen Gegen flavonoids Juncus roemerianus Cardamun Lyciumbarbarum Salvia miltiorrhiza Fenugreek
B Baicalin Salviae miltiorrhizae Puerarin Chrysin Tetrandrine Baicalein Glycyrrhizic acid Atractylodes
C Pachyman Rhodioloside Clove Formononetin Artichoke Angelica sinensis Sennoside Salt black bean
D Tribulus terrestris saponins Ligustilide Kudzu Semen plantaginis Nutmeg 2 Resveratrol Spinach Garlic Polysaccharide
E Daidzein Citrus Radix glycyrrhizae Soybean isoflavone Hordenine Cortex albiziae Raspberry Puerarialobata flavone 2
F Polygonum multiflorum Hyperforin Cinnamon Paecilomyces bepiali chen Allicin Hesperidin TP (tea polyphenol) Control

Figure 1.

Figure 1

The expression of Collagen I obviously decreased after the treatment of Lichen extracts in H9c2 cells. A. Immunofluorescence staining of Collagen I. A: Lichen. B: DMSO. After 48 h treatment with 20 μg/ml Lichen extracts, Collagen I expression level significantly down regulated, comparing with the control. B. Collagen I expression level changes with time and concerntration of Lichen extracts. (The Collagen I expression level decreased before 48 hrs treatment, after 48 hrs, Collagen I level beacomes stable). (Primers used, F: 5’-GGCTTCTTCAAACCACTGCTTT-3’, R: 5’-AAAGTCATAGCCACCTCCGCTG-3’). C. Immunoblotting assay (Collagen I decreased with time, comparing with Actin (Control) Collagen I protein level goes down with time. The results are almost the same with the Q-PCR results.

We also harvested the H9c2 cells treated with different concentrations (10 μg/mL, 20 μg/mL and 30 μg/mL) of Lichen extracts at different time points and extracted RNA from them to make sure that the immunofluorescence staining results were reliable, and find the optimal conditions for Lichen to inhibit the expression of collagen I in H9c2 cells. As is shown in Figure 1B, the Collagen I expression level decreased in the first 48 h treatment and did not go down any more as time went on. The results of western blotting also confirmed the results of q-PCR (Figure 1C).

Expression levels of AF associated genes were changed after the treatment of lichen extraction

Although the exact genes responsible for AF in this region remain unclear, the scientific results instigated exploring the genetic characteristics of atrial fibrillation. So, based on the publications, we detected the expression levels of some genes associated with AF, including Acta2 , Ctgf, Grem1, Bmp7, Col1a2, Col3a1, Lox, Mmp3, Mmp8, Mmp9, and Serpine1. Accroding to the results of qPCR, Bmp7, Lox, Mmp3, Mmp8, Mmp9, and Serpine I were upregulated; and Acta2, Ctgf, Grem1, Col1a2, Col3a1 were down regulated compared with control (Figure 2A). The results were then comfirmed by western blotting analysis (Figure 2B, 2C).

Figure 2.

Figure 2

The expression of AF-realated genes were changed after 48 h of Lichen extracts treatment in H9c2 cells. A. Real-time quantitative analysis of atrial fibrillation transcription related genes expression (Lichen processing H9C2 cells after 48 hours, using real-time quantitative PCR to detect AF gene transcription level changes (P<0.001 Experimental groups VS. Control groups). B. Western blotting analysis (1: DMSO, 2: Lichen extracts.) Pro-Fibrotic: Acta2, Ctgf, Grem1, Anti-Fibrotic: Bmp7, Extracellular Matrix (ECM) Structural Constituents: Col1a2, Col3a1. Extracellular Matrix (ECM) Remodeling Enzymes: Lox, Mmp3, Mmp8, Mmp9, Serpine1 (mediates inhibition of fibrinolysis by inhibiting the activity of plasminogen activator). C. The column chart results of Western blotting. *P<0.05, **P<0.01, compared with DMSO treatment.

Expression levels of BMP7 and miR-194-5p in HCM were changed after the treatment of lichen extraction

In order to investigate the correlation between BMP7 and miR-194-5p during the process myocardial cells are treated with Lichen extraction, we detected the changes of BMP7 and miR-194-5p expressions before and after Human Cardiac Myocytes (HCM) were treated with Lichen extraction. Interestingly, the mRNA level of miR-194-5p significantly decreased after the treatment of Lichen extracts while both the mRNA and protein levels of BMP7 evidently increased simultaneously (Figure 3).

Figure 3.

Figure 3

The expression of of miR-194-5p and BMP7 were reversely changed after the treatment of Lichen extracts in HCM. A. The mRNA expressions of miR-194-5p and BMP7 were reversely changed after the treatment of Lichen extracts in HCM. B, C. The protein level of BMP7 were significantly increased by Lechen extract in 48 h in HCM. *P<0.05, **P<0.01, compared with DMSO treatment.

Inverse relationship between expression of BMP7 and miR-194-5p

To validate whether miR-194-5p directly targets the 3’UTRs of BMP7 mRNA or not, we cloned a sequence with the predicted target sites of miR-194-5p or a mutated sequence with the predicted target sites to downstream of the pMIR luciferase reporter gene. When the wild-type or mutation-type vector was transfected with miR-194-5p, the luciferase activity of wild-type vector was significantly decreased (P<0.01) compared with mutation-type vector (Figure 4A). While the wild-type or mutation-type vector was transfected with negative control miRNA, there was no significant difference between the wild-type or mutation-type vector. These data suggested that miR-194-5p may play a major role in the regulation of BMP7. Taken together, these data indicated that the 3’UTR of BMP7 is a functional target site for miR-194-5p in HCM.

Figure 4.

Figure 4

Luciferase activity assay results of miR-194-5p and BMP7, as well as the expression changes of miR-194-5p and BMP7 caused by Lichen extracts in HCM overexpressing miR-194-5p. A. There is a specific targeting reaction between miR-194-5p and BMP7. B. Lichen extracts could reduce the expression of miR-194-5p in both normal HCM and HCM overexpressing miR-194-5p to increase the expression of BMP7. C. The expressions of miR-194-5p and BMP7 at protein level changed in line with the mRNA level. D. The protein level of BMP-7 in the column chart. *P<0.05, **P<0.01, compared with DMSO treatment; #P<0.05, ##P<0.01, compared with Lichen treatment.

Lichen could always inhibit the expression of miR-194-5p to increase the expression of BMP7 in HCM

As is shown above, it was already proved that BMP7 is the target of miR-194-5p, which means the increase of BMP7 expression might be the result of miR-194-5p depletion. In order to confirm whether Lichen could increase the expression of BMP7 through inhibiting the expression of miR-194-5p, we determined the mRNA levels of BMP7 and miR-194-5p in HCM before and after the treatment of Lichen on the conditions that miR-194-5p was over-expressed or not. As is shown in Figure 4B, Lichen could depress the expression of miR-194-5p in HCM no matter miR-194-5p was overexpressed or not and correspondingly, the expression of BMP7 could be increased in both conditions.

Discussion

AF is a problem of growing proportions that has been termed “epidemic” [42]. Present therapeutic options have limited efficacy and disconcerting adverse-effect risks. Consequently, a variety of novel, mechanism-based approaches are in development. One approach has been developed to target atrial remodeling, with the use of “upstream therapy” interventions that interfere with putative signaling pathways. Interventions, such as omega-3 fatty acids and renin-angiotensin system inhibitors, were reported to work through preventing atrial remodeling in experimental models [43]. While retrospective analysis of clinical data is promising, the few prospective randomized clinical trials which are completed to date have been negative or inconclusive [43]. Even though the notion of remodeling prevention is very attractive, its feasibility remains to be demonstrated. Although the underlying mechanisms of AF are complex and not well understood yet, people have already put forward multiple potential pathways. A better understanding of the genetic mechanism underlying AF will hopefully lead to an accurate risk stratification of AF [44].

Current management strategies for AF have had some developments; However, some challenges still remain to be solvedin this field. For example, we still cannot fully understand the early identification of AF in patients who are at risk andlittle progress hasbeen made in pharmaceuticals. Some groups, for example, Husser et al [45] and his group included a total of 195 consecutive patients with drug refractory paroxysmal or persistent AF who underwent AF catheter ablation, and were the first to genotype two common variants, rs2200733 and rs10033464 on chromosome 4q25, which were independently associated with an increased risk of recurrence of AF after catheter ablation. Another group [46] investigated the variations in the human soluble epoxide hydrolase gene responsible for recurrence of AF after catheter ablation and described that the rs751141 polymorphism of the EPHX2 gene is associated with a significantly increased risk of AF. These results point to a potential role for these common variants and may guide differential therapy in the future. Although, there are many genes related to AF and have been published, there is no prognostic or therapeutic impact derived from an AF genetic test result. However, it still very valuable if we could find some chemical components which would alter the AF associated genes’ expression.

In this study, we have investigated the effects Lichen extracts has on several AF related genes including miR-194-5p and BMP7 in H9c2 cells and HCM, as well as the mechanism underlying the corresponding changes of miR-194-5p and BMP7 in Lichen-treated HCM. According to Figure 1, Collagen I expression in H9c2 cells could be significantly decreased by the treatment of Lichen extracts, which could help prevent atrial fibrosis of organs to protect heart from AF. In order to explore more about the effect of Lichen extracts has on preventing AF, expression of more genes concerning AF in H9c2 cells were detected before and after the treatment of Lichen extracts. All the genes expression changed to reduce the risk of AF after the treatment of Lichen extracts as we predicted except MMPs. There is one possibility that the way MMPs influence is complicated and several relevant factors could affect each other through various pathways, so more research needs to be performed to figure out the reason why MMPs were upregulated in H9c2 cells after Lichen extracts treatment.

Because of the predicted targeting action between miR-194-5p and BMP7 [35], we hypothesized that Lichen extractsupregulated the expression of BMP7 through inhibiting the expression of miR-194-5p and performed luciferase activity assay to confirm the targeting reaction between miR-194-5p and BMP7. According to the corresponding changes of expression levels of miR-194-5p and BMP7 in miR-194-5p-overexpressed HCM before and after the treatment of Lichen, it was demonstrated that Lichen could regulate the expression of BMP7 through regulating mRNA level of miR-194-5p in HCM to decrease the risk of AF in human.

Based on the achievements in the past several years, our results, in a way, show the clinical implications of exploring the genetic basis of AF and will have more impacts on screening for pharmaceuticals which would release the pain the patients suffer from.

While, more research needs to be carried out to explore the specific relationship between atrial fibrosis and AF to solidify our result, and more tests in vivo also need to be performed to make our result easier to apply on clinic in the future.

Disclosure of conflict of interest

None.

References

  • 1.Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. Health Technol Assess. 2005;9:1–74. doi: 10.3310/hta9400. [DOI] [PubMed] [Google Scholar]
  • 2.Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin. 2009;27:13–24. doi: 10.1016/j.ccl.2008.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Beyerbach DM, Zipes DP. Mortality as an endpoint in atrial fibrillation. Heart Rhythm. 2004;1:B8–18. doi: 10.1016/j.hrthm.2004.04.018. [DOI] [PubMed] [Google Scholar]
  • 4.European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Camm AJ. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Europace. 2010;12:1360–1420. doi: 10.1093/europace/euq350. [DOI] [PubMed] [Google Scholar]
  • 5.Munger TM, Wu LQ, Shen WK. Atrial fibrillation. J Biomedi Res. 2014;28:1–17. doi: 10.7555/JBR.28.20130191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, Brugada J, Girona J, Domingo A, Bachinski LL, Roberts R. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med. 1997;336:905–911. doi: 10.1056/NEJM199703273361302. [DOI] [PubMed] [Google Scholar]
  • 7.Magnani JW, Rienstra M, Lin H, Sinner MF, Lubitz SA, McManus DD, Dupuis J, Ellinor PT, Benjamin EJ. Atrial fibrillation, current knowledge and future directions in epidemiology and genomics. Circulation. 2011;124:1982–1993. doi: 10.1161/CIRCULATIONAHA.111.039677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Chen YH, Xu SJ, Bendahhou S. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299:251–254. doi: 10.1126/science.1077771. [DOI] [PubMed] [Google Scholar]
  • 9.Makiyama T, Akao M, Shizuta S, Doi T, Nishiyama K, Oka Y, Ohno S, Nishio Y, Tsuji K, Itoh H, Kimura T, Kita T, Horie M. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J Am Coll Cardiol. 2008;52:1326–1334. doi: 10.1016/j.jacc.2008.07.013. [DOI] [PubMed] [Google Scholar]
  • 10.Yang Y, Li J, Lin X, Yang Y, Hong K, Wang L, Liu J, Li L, Yan D, Liang D, Xiao J, Jin H, Wu J, Zhang Y, Chen YH. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet. 2009;54:277–283. doi: 10.1038/jhg.2009.26. [DOI] [PubMed] [Google Scholar]
  • 11.Olson TM, Alekseev AE, Liu XK, Park S, Zingman LV, Bienengraeber M, Sattiraju S, Ballew JD, Jahangir A, Terzic A. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet. 2006;15:2185–2191. doi: 10.1093/hmg/ddl143. [DOI] [PubMed] [Google Scholar]
  • 12.Yang T, Yang P, Roden DM, Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm. 2010;7:1246–1252. doi: 10.1016/j.hrthm.2010.05.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yang YQ, Li L, Wang J, Zhang XL, Li RG, Xu YJ, Tan HW, Wang XH, Jiang JQ, Fang WY, Liu X. GATA6 loss-of-function mutation in atrial fibrillation. Eur J Med Genet. 2012;55:520–526. doi: 10.1016/j.ejmg.2012.06.007. [DOI] [PubMed] [Google Scholar]
  • 14.Ellinor PT, Lunetta KL, Albert CM. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–675. doi: 10.1038/ng.2261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Nishida K, Michael G, Dobrev D, Nattel S. animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace. 2010;12:160–172. doi: 10.1093/europace/eup328. [DOI] [PubMed] [Google Scholar]
  • 16.Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C, Christ T, Schüler S, Ravens U. Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I (K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104:2551–2557. doi: 10.1161/hc4601.099466. [DOI] [PubMed] [Google Scholar]
  • 17.Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as antagonist of organ fibrosis. Front Biosci. 2009;14:4992–5012. doi: 10.2741/3583. [DOI] [PubMed] [Google Scholar]
  • 18.Adam O, Theobald K, Lavall D, Grube M, Kroemer HK, Ameling S, Schäfers HJ, Böhm M, Laufs U. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J Mol Cell Cardiol. 2011;50:678–685. doi: 10.1016/j.yjmcc.2010.12.019. [DOI] [PubMed] [Google Scholar]
  • 19.Wolke C, Bukowska A, Goette A, Lendeckel U. Redox control of cardiac remodeling in atrial fibrillation. Biochim Biophys Acta. 2015;1850:1555–1565. doi: 10.1016/j.bbagen.2014.12.012. [DOI] [PubMed] [Google Scholar]
  • 20.Lewkowicz J, Knapp M, Tankiewicz-Kwedlo A, Sawicki R, Kamińska M, Waszkiewicz E, Musiał WJ. MMP-9 in atrial remodeling in patients with atrial fibrillation. Ann Cardiol Angeiol. 2015;64:285–291. doi: 10.1016/j.ancard.2014.12.004. [DOI] [PubMed] [Google Scholar]
  • 21.Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary by pass. Circulation. 2007;116:I1–17. doi: 10.1161/CIRCULATIONAHA.106.677906. [DOI] [PubMed] [Google Scholar]
  • 22.Maass AH, De Jong AM, Smit MD, Gouweleeuw L, de Boer RA, Van Gilst WH, Van Gelder IC. Cardiac gene expression profiling - the quest for an atrium-specific biomarker. Neth Heart J. 2010;18:610–614. doi: 10.1007/s12471-010-0844-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Fukui A, Takahashi N, Nakada C, Masaki T, Kume O, Shinohara T, Teshima Y, Hara M, Saikawa T. Role of leptin signaling in the pathogenesis of angiotensin II-mediated atrial fibrosis and fibrillation. Circ Arrhythm Electrophysiol. 2013;6:402–409. doi: 10.1161/CIRCEP.111.000104. [DOI] [PubMed] [Google Scholar]
  • 24.Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011;10:945–963. doi: 10.1038/nrd3599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hall-Glenn F, Lyons KM. Roles for CCN2 in normal physiological processes. Cell Mol Life Sci. 2011;68:3209–3217. doi: 10.1007/s00018-011-0782-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kubota S, Takigawa M. The role of CCN2 in cartilage and bone development. J Cell Commun Signal. 2011;5:209–21. doi: 10.1007/s12079-011-0123-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zuniga A, Haramis AP, McMahon AP, Zeller R. Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. Nature. 1999;401:598–602. doi: 10.1038/44157. [DOI] [PubMed] [Google Scholar]
  • 28.Zuniga A, Michos O, Spitz F. Mouse limb deformity mutations disrupt a global control region within the large regulatory landscape required for Gremlin expression. Genes Dev. 2004;18:1553–1564. doi: 10.1101/gad.299904. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bénazet JD, Bischofberger M, Tiecke E, Gonçalves A, Martin JF, Zuniga A, Naef F, Zeller R. A self-regulatory system of interlinked signaling feedback loops controls mouse limb patterning. Science. 2009;323:1050–1053. doi: 10.1126/science.1168755. [DOI] [PubMed] [Google Scholar]
  • 30.Retief E, Parker MI, Retief AE. Regional chromosome mapping of human collagen genes alpha 2(I) and alpha 1(I) (COLIA2 and COLIA1) Hum Genet. 1985;69:304–308. doi: 10.1007/BF00291646. [DOI] [PubMed] [Google Scholar]
  • 31.Wenstrup RJ, Cohn DH, Cohen T, Byers PH. Arginine for glycine substitution in the triple-helical domain of the products of one alpha 2(I) collagen allele (COL1A2) produces the osteogenesis imperfecta type IV phenotype. J Biol Chem. 1988;263:7734–7740. [PubMed] [Google Scholar]
  • 32.Hosper NA, van den Berg PP, de Rond S, Popa ER, Wilmer MJ, Masereeuw R, Bank RA. Epithelial-to-mesenchymal transition in fibrosis: collagen type I expression is highly upregulated after EMT, but does not contribute to collagen deposition. Exp Cell Res. 2013;319:3000–3009. doi: 10.1016/j.yexcr.2013.07.014. [DOI] [PubMed] [Google Scholar]
  • 33.Anumonwo JM, Kalifa J. Risk factors and genetics of atrial fibrillation. Cardiol Clin. 2014;32:485–494. doi: 10.1016/j.ccl.2014.07.007. [DOI] [PubMed] [Google Scholar]
  • 34.Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial fibrillation in developing countries. Int J Cardiol. 2013;167:2412–2420. doi: 10.1016/j.ijcard.2013.01.184. [DOI] [PubMed] [Google Scholar]
  • 35.Yang JH, Li JH, Shao P, Zhou H, Chen YQ, Qu LH. starBase: a database for exploring microRNA-mRNA interaction maps from argonaute CLIP-Seq and degradome-Seq data. Nucleic Acids Res. 2011;39:202–209. doi: 10.1093/nar/gkq1056. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, Kawahara Y, Komuro I. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res. 2013;113:322–326. doi: 10.1161/CIRCRESAHA.113.301209. [DOI] [PubMed] [Google Scholar]
  • 37.Stamboul K, Lorin J, Lorgis L, Guenancia C, Beer JC, Touzery C, Rochette L, Vergely C, Cottin Y, Zeller M. Atrial fibrillation is associated with a marker of endothelial function and oxidative stress in patients with acute myocardial infarction. PLoS One. 2015;10:e0131439. doi: 10.1371/journal.pone.0131439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Jabre P, Jouven X, Adnet F, Thabut G, Bielinski SJ, Weston SA, Roger VL. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011;123:2094–2100. doi: 10.1161/CIRCULATIONAHA.110.990192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038–1045. doi: 10.1093/eurheartj/ehn579. [DOI] [PubMed] [Google Scholar]
  • 40.Stamboul K, Zeller M, Fauchier L, Gudjoncik A, Buffet P, Garnier F, Guenancia C, Lorgis L, Beer JC, Touzery C, Cottin Y. Incidence and prognostic significance of silent atrial fibrillation in acute myocardial infarction. Int J Cardiol. 2014;174:611–617. doi: 10.1016/j.ijcard.2014.04.158. [DOI] [PubMed] [Google Scholar]
  • 41.Shen R, Pan S, Qi S, Lin X, Cheng S. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun. 2010;394:1047–1052. doi: 10.1016/j.bbrc.2010.03.121. [DOI] [PubMed] [Google Scholar]
  • 42.Cardin S, Libby E, Pelletier P, Le Bouter S, Shiroshita-Takeshita A, Le Meur N, Léger J, Demolombe S, Ponton A, Glass L, Nattel S. Contrasting gene expression profiles in two canine models of atrial fibrillation. Circ Res. 2007;100:425–433. doi: 10.1161/01.RES.0000258428.09589.1a. [DOI] [PubMed] [Google Scholar]
  • 43.Chen LY, Shen WK. Epidemiology of atrial fibrillation: a current perspective. Heart Rhythm. 2007;4:1–6. doi: 10.1016/j.hrthm.2006.12.018. [DOI] [PubMed] [Google Scholar]
  • 44.Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Europace. 2011;13:308–328. doi: 10.1093/europace/eur002. [DOI] [PubMed] [Google Scholar]
  • 45.Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2010;55:747–753. doi: 10.1016/j.jacc.2009.11.041. [DOI] [PubMed] [Google Scholar]
  • 46.Wutzler A, Kestler C, Perrot A, Loehr L, Huemer M, Parwani AS, Attanasio P, Özcelik C, Schunck WH, Gollasch M, Haverkamp W, Boldt LH. Variations in the human soluble epoxide hydrolase gene and recurrence of atrial fibrillation after catheter ablation. Int J Cardiol. 2013;168:3647–3651. doi: 10.1016/j.ijcard.2013.05.010. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Clinical and Experimental Pathology are provided here courtesy of e-Century Publishing Corporation

RESOURCES